NovoCure annual net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
NovoCure Net Income Growth & History (NVCR)
NovoCure's net income was −$136.2M for fiscal 2025.
View full NovoCure company overviewNovoCure annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$136.2M | $32.4M | — |
| 2024 | 2024-12-31 | −$168.6M | $38.4M | — |
| 2023 | 2023-12-31 | −$207.0M | −$114.5M | — |
| 2022 | 2022-12-31 | −$92.5M | −$34.2M | — |
| 2021 | 2021-12-31 | −$58.4M | −$78.2M | — |
| 2020 | 2020-12-31 | $19.8M | $27.0M | — |
| 2019 | 2019-12-31 | −$7.2M | $56.3M | — |
| 2018 | 2018-12-31 | −$63.6M | −$1.9M | — |
| 2017 | 2017-12-31 | −$61.7M | $70.2M | — |
| 2016 | 2016-12-31 | −$131.8M | −$20.3M | — |
| 2015 | 2015-12-31 | −$111.6M | −$30.9M | — |
| 2014 | 2014-12-31 | −$80.7M | −$3.3M | — |
| 2013 | 2013-12-31 | −$77.4M | — | — |
NovoCure quarterly net income
Q3.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$15.7M | $24.5M | — |
| Q1 2026 | 2026-03-31 | −$71.1M | −$36.8M | — |
| Q4 2025 | 2025-12-31 | −$24.5M | $41.4M | — |
| Q3 2025 | 2025-09-30 | −$37.3M | −$6.7M | — |
| Q2 2025 | 2025-06-30 | −$40.1M | −$6.8M | — |
| Q1 2025 | 2025-03-31 | −$34.3M | $4.4M | — |
| Q4 2024 | 2024-12-31 | −$65.9M | −$18.8M | — |
| Q3 2024 | 2024-09-30 | −$30.6M | $18.9M | — |
| Q2 2024 | 2024-06-30 | −$33.4M | $24.0M | — |
| Q1 2024 | 2024-03-31 | −$38.8M | $14.3M | — |
| Q4 2023 | 2023-12-31 | −$47.1M | −$9.8M | — |
| Q3 2023 | 2023-09-30 | −$49.5M | −$22.9M | — |
| Q2 2023 | 2023-06-30 | −$57.4M | −$33.4M | — |
| Q1 2023 | 2023-03-31 | −$53.1M | −$48.4M | — |
| Q4 2022 | 2022-12-31 | −$37.3M | −$10.8M | — |
| Q3 2022 | 2022-09-30 | −$26.6M | −$13.5M | — |
| Q2 2022 | 2022-06-30 | −$24.0M | −$9.4M | — |
| Q1 2022 | 2022-03-31 | −$4.6M | −$519,000 | — |
| Q4 2021 | 2021-12-31 | −$26.5M | −$31.4M | — |
| Q3 2021 | 2021-09-30 | −$13.1M | −$22.4M | — |
| Q2 2021 | 2021-06-30 | −$14.6M | −$16.3M | — |
| Q1 2021 | 2021-03-31 | −$4.1M | −$8.1M | — |
| Q4 2020 | 2020-12-31 | $4.9M | $657,000 | +15.42% |
| Q3 2020 | 2020-09-30 | $9.3M | $7.4M | +381.04% |
| Q2 2020 | 2020-06-30 | $1.7M | $2.9M | — |
| Q1 2020 | 2020-03-31 | $4.0M | $16.1M | — |
| Q4 2019 | 2019-12-31 | $4.3M | $19.9M | — |
| Q3 2019 | 2019-09-30 | $1.9M | $13.6M | — |
| Q2 2019 | 2019-06-30 | −$1.3M | $14.2M | — |
| Q1 2019 | 2019-03-31 | −$12.2M | $8.6M | — |
| Q4 2018 | 2018-12-31 | −$15.6M | −$4.7M | — |
| Q3 2018 | 2018-09-30 | −$11.7M | −$196,000 | — |
| Q2 2018 | 2018-06-30 | −$15.5M | $5.7M | — |
| Q1 2018 | 2018-03-31 | −$20.7M | −$2.7M | — |
| Q4 2017 | 2017-12-31 | −$10.9M | $11.2M | — |
| Q3 2017 | 2017-09-30 | −$11.5M | $22.1M | — |
| Q2 2017 | 2017-06-30 | −$21.2M | $19.4M | — |
| Q1 2017 | 2017-03-31 | −$18.0M | $17.4M | — |
| Q4 2016 | 2016-12-31 | −$22.2M | $10.8M | — |
| Q3 2016 | 2016-09-30 | −$33.6M | −$7.6M | — |
| Q2 2016 | 2016-06-30 | −$40.6M | −$11.3M | — |
| Q1 2016 | 2016-03-31 | −$35.4M | −$12.2M | — |
| Q4 2015 | 2015-12-31 | −$32.9M | — | — |
| Q3 2015 | 2015-09-30 | −$26.0M | −$7.7M | — |
| Q2 2015 | 2015-06-30 | −$29.4M | — | — |
| Q1 2015 | 2015-03-31 | −$23.3M | — | — |
| Q3 2014 | 2014-09-30 | −$18.3M | — | — |
NovoCure net income trends
Over the last five fiscal years, NovoCure's net income decreased from $19.8M to −$136.2M, a change of −$156.0M. The latest reported quarter, Q2 2026, shows −$15.7M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NovoCure source filings ↗Community posts
Novocure raises annual revenue and EBITDA targets as patient numbers grow
Novocure ($NVCR) lifted its 2026 revenue forecast to $736–$743 million from $710–$725 million and its adjusted EBITDA outlook to $24–$34 million from $0–$15 million. Third-quarter 2026 revenue increased 16% to $193.4 million, supported by 1 ...
